W Janni

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, H. A. Burris et al. · Annals of Oncology · 2018 · 839 citations · Full text

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

G. N. Hortobágyi, Salomon M. Stemmer, H.A. Burris et al. · Annals of Oncology · 2021 · 73 citations

Endocrine Oncology, Breast Oncology, Phase Iii Monaleesa-2 +9

Obstetrical parameters influencing the duration of the second stage of labor

W Janni, Katharina Jundt, Gerhard Rammel et al. · European Journal of Obstetrics & Gynecology and Reproductive Biology · 2004 · 55 citations

Second Stage, Fertility, Preterm Labor +12

Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: The German SUCCESS-Trial

Brigitte Rack, Christian Schindlbeck, J. Hilfrich et al. · Journal of Clinical Oncology · 2008 · 47 citations

Breast Oncology, Initially Ctc, Immunology +19